The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol
Abstract
Objective: Allopurinol is the most commonly used urate‐lowering therapy in gout. Allopurinol hypersensitivity syndrome (AHS) is a rare but potentially fatal adverse event. Dosing guidelines based on creatinine clearance have been proposed based on the recognition that dosages of ≥300 mg/day may be associated with AHS, particularly in patients with renal impairment. However, the relationship between the allopurinol starting dose and AHS is unknown. This study was undertaken to determine the relationship between allopurinol dosing and AHS. Methods: A retrospective case–control study of patients with gout who developed AHS between January 1998 and September 2010 was undertaken. For each case, 3 controls with gout who were receiving allopurinol but did not develop AHS were identified. Controls were matched with cases for sex, diuretic use at the time of initiating allopurinol, age (±10 years), and estimated glomerular filtration rate (estimated GFR). Starting dose and dose at the time of the reaction in cases were compared between cases and controls. Results: Fifty‐four AHS cases and 157 controls were identified. There was an increase in the risk of AHS as the starting dose of allopurinol corrected for the estimated GFR increased. For the highest quintile of starting dose per estimated GFR, the odds ratio was 23.2 (P < 0.01). Receiver operating characteristic analysis indicated that 91% of AHS cases and 36% of controls received a starting dose of allopurinol of ≥1.5 mg per unit of estimated GFR (mg/ml/minute). Conclusion: Our findings indicate that starting allopurinol at a dose of 1.5 mg per unit of estimated GFR may be associated with a reduced risk of AHS. In patients who tolerate allopurinol, the dose can be gradually increased to achieve the target serum urate level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Zhang, W., Doherty, M., Bardin, T., Pascual, E., Barskova, V, Conaghan, P., Gerster, J., Jacobs, J., Leeb, B., Lioté, F., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055269 · Cited by 1,407
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284
Hande, K. R., Noone, R. M., & Stone, W. J. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90743-5 · Cited by 680
Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f3ef9c · Cited by 624
Jordan, K. M., Cameron, J. S., Snaith, M., Zhang, W., Doherty, M., Seckl, J., Hingorani, A., Jaques, R., & Nuki, G. (2007) · Rheumatology · doi:10.1093/rheumatology/kem056a · Cited by 552
Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout
Perez‐Ruiz, F., Calabozo, M., Pijoan, J. I., Herrero‐Beites, A. M., & Ruibal, A. (2002) · Arthritis Care & Research · doi:10.1002/art.10511 · Cited by 454
Shoji, A., Yamanaka, H., & Kamatani, N. (2004) · Arthritis Care & Research · doi:10.1002/art.20405 · Cited by 438
Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., Sawada, J.-I., Furuya, H., Takahashi, Y., Muramatsu, M., et al. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1617 · Cited by 410
Tassaneeyakul, W., Jantararoungtong, T., Chen, P., Lin, P.-Y., Tiamkao, S., Khunarkornsiri, U., Chucherd, P., Konyoung, P., Vannaprasaht, S., Choonhakarn, C., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328330a3b8 · Cited by 401
Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.
Borstad, G. C., Bryant, L. R., Abel, M. P., Scroggie, D. A., Harris, M. D., & Alloway, J. A. (2004) · PubMed · Cited by 328
Allopurinol Hypersensitivity Syndrome: A Review
Arellano, F., & Sacristán, J. A. (1993) · Annals of Pharmacotherapy · doi:10.1177/106002809302700317 · Cited by 318
Stamp, L. K., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., & Chapman, P. T. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30119 · Cited by 233
Self-citationDalbeth, N., Kumar, S., Stamp, L. K., & Gow, P. J. (2006) · PubMed · Cited by 226
Self-citationRelation between adverse events associated with allopurinol and renal function in patients with gout
Vázquez-Mellado, J., Morales, E. M., Pacheco-Tena, C., & Burgos-Vargas, R. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.10.981 · Cited by 169
Acute adverse reactions attributed to allopurinol in hospitalised patients.
McInnes, G. T., Lawson, D. H., & Jick, H. (1981) · Annals of the Rheumatic Diseases · doi:10.1136/ard.40.3.245 · Cited by 160
Dalbeth, N., & Stamp, L. K. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00270.x · Cited by 153
Self-citationJung, J., Song, W., Kim, Y.-S., Joo, K. W., Lee, K., Kim, S.-H., Park, H., Chang, Y., Cho, S., Min, K. ‐., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr060 · Cited by 138
Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout
McCarthy, G., Barthelemy, C. R., Veum, J. A., & Wortmann, R. L. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780341203 · Cited by 84
PLASMA OXIPURINOL CONCENTRATIONS DURING ALLOPURINOL THERAPY
Emmerson, B. T., Gordon, R. B., CROSS, M., & Thomson, D. B. (1987) · Rheumatology · doi:10.1093/rheumatology/26.6.445 · Cited by 73
Al-Kawas, F. H., SEEFF, L. B., BERENDSON, R. A., Zimmerman, H. J., & ISHAK, K. G. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-95-5-588 · Cited by 64
Kano, Y., Hirahara, K., Asano, Y., & Shiohara, T. (2008) · Acta Dermato Venereologica · doi:10.2340/00015555-0528 · Cited by 39
Cited by
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21772 · Cited by 1,536
Self-citationDalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00569-9 · Cited by 1,338
Self-citationDalbeth, N., Merriman, T. R., & Stamp, L. K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00346-9 · Cited by 1,087
Self-citation2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello‐Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24180 · Cited by 983
Self-citation
Metadata
- Authors
- Stamp, L. K., Taylor, W. J., Jones, P. B., Dockerty, J. L., Drake, J., Frampton, C., & Dalbeth, N.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-07-27
- Volume
- 64
- Issue
- 8
- Pages
- 2529-2536
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2055631257
- Cited by
- 296
- References
- 22
- FWCI
- 14.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.